Back to Results

Mainz Biomed BV (QUCY)

Mainz Biomed BV (NASDAQ: QUCY) is listed as a structured product or certificate tied to Mainz Biomed N.V., a healthcare company focused on biotechnology and in-vitro diagnostics. The underlying business develops and commercializes tests for early cancer detection in the United States and Europe. Its product portfolio includes ColoAlert, a molecular genetic stool test for colorectal cancer screening, and PancAlert, a stool-based test under development for pancreatic cancer detection. The company also operates a clinical diagnostic laboratory and distributes IVD kits to third-party laboratories. Mainz Biomed maintains a collaboration with Thermo Fisher Scientific Inc. related to colorectal cancer screening product development and commercialization. The company was founded in 2008 and is based in Mainz, Germany.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-QUCY
—
—
—
$14 1,057.1% Upside
—
Bargain
Fair
—
—
—
0.0%
September 9, 2026
—
—
—
26.41 M
—
—
87.5%
—
—
—
Send a message
Valuation • Fair Value

Mainz Biomed BV (NASDAQ-QUCY) Fair Value by Valuation Model

Compare the primary fair value estimate for Mainz Biomed BV (NASDAQ-QUCY) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

Not available

Data is currently unavailable.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

NM

Comparable-company valuation reference.

Analyst Price Target

$14 1,057.1% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use this section to compare the primary fair value estimate for Mainz Biomed BV (NASDAQ-QUCY) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Mainz Biomed BV (NASDAQ-QUCY)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

537.08 K

Current operating scale indicator.

Revenue Forecast

Not available

Data is currently unavailable.

EBITDA

-12.703 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Mainz Biomed BV (NASDAQ-QUCY) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Mainz Biomed BV (NASDAQ-QUCY)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

Not available

Data is currently unavailable.

Beneish M-Score

Not available

Data is currently unavailable.

Altman Z-Score

Not available

Data is currently unavailable.

FCF / Net Income

Not available

Data is currently unavailable.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Mainz Biomed BV (NASDAQ-QUCY). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Mainz Biomed BV (NASDAQ-QUCY)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

September 9, 2026

Days to Earnings

50

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Mainz Biomed BV (NASDAQ-QUCY), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Mainz Biomed BV (NASDAQ-QUCY) Stock Forecast & Technical Outlook

Review Mainz Biomed BV (NASDAQ-QUCY) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Mainz Biomed BV (NASDAQ-QUCY) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Mainz Biomed BV (NASDAQ-QUCY) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Mainz Biomed BV (NASDAQ-QUCY) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Mainz Biomed BV (NASDAQ-QUCY) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Mainz Biomed BV (NASDAQ-QUCY) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Mainz Biomed BV (NASDAQ-QUCY)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Mainz Biomed BV (NASDAQ-QUCY) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 0
FAQ • Fast Investor Answers

Mainz Biomed BV (NASDAQ-QUCY) Stock FAQ

Quick answers about Mainz Biomed BV (NASDAQ-QUCY) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
Not available
Data is currently unavailable
Valuation Rating
Not available
Classification is not available
Analyst Target
$14 1,057.1% Upside
Data is currently unavailable
Financial Health
Fair
Current financial-health read

A fair value estimate for Mainz Biomed BV (NASDAQ-QUCY) is not currently available in the latest data file.

A clear undervalued or overvalued classification is not currently available in the latest data file.

The available analyst price target for Mainz Biomed BV (NASDAQ-QUCY) is $14 1,057.1% Upside.

The current financial health read for Mainz Biomed BV (NASDAQ-QUCY) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Mainz Biomed BV (NASDAQ-QUCY) is September 9, 2026.

Based on the current data, dividend yield is 0.0%.

The current market capitalization listed for Mainz Biomed BV is 26.41 M.

The ticker symbol for Mainz Biomed BV is NASDAQ-QUCY, and the stock is listed on NASDAQ.

Mainz Biomed BV (NASDAQ-QUCY) is listed on NASDAQ.

The free float listed for Mainz Biomed BV is 87.5%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on NASDAQ View more

Amgen Inc (AMGN) Amgen Inc (AMGN)
Gilead Sciences Inc (GILD) Gilead Sciences Inc (GILD)
Vertex Pharmaceuticals Inc (VRTX) Vertex Pharmaceuticals Inc (VRTX)
Regeneron Pharmaceuticals Inc (REGN) Regeneron Pharmaceuticals Inc (REGN)
Argenx NV ADR (ARGX) Argenx NV ADR (ARGX)
Revolution Medicines Inc (RVMD) Revolution Medicines Inc (RVMD)
Natera Inc (NTRA) Natera Inc (NTRA)
Alnylam Pharmaceuticals Inc (ALNY) Alnylam Pharmaceuticals Inc (ALNY)
BeOne Medicines AG DRC (ONC) BeOne Medicines AG DRC (ONC)
Biogen Inc (BIIB) Biogen Inc (BIIB)
Roivant Sciences Ltd (ROIV) Roivant Sciences Ltd (ROIV)
Moderna Inc (MRNA) Moderna Inc (MRNA)
BioNTech SE (BNTX) BioNTech SE (BNTX)
Insmed Inc (INSM) Insmed Inc (INSM)
Incyte Corporation (INCY) Incyte Corporation (INCY)
United Therapeutics Corporation (UTHR) United Therapeutics Corporation (UTHR)
Neurocrine Biosciences Inc (NBIX) Neurocrine Biosciences Inc (NBIX)
Genmab AS (GMAB) Genmab AS (GMAB)
BridgeBio Pharma Inc (BBIO) BridgeBio Pharma Inc (BBIO)
Ascendis Pharma AS (ASND) Ascendis Pharma AS (ASND)
Exelixis Inc (EXEL) Exelixis Inc (EXEL)
Madrigal Pharmaceuticals Inc (MDGL) Madrigal Pharmaceuticals Inc (MDGL)
Abivax SA ADR (ABVX) Abivax SA ADR (ABVX)
Biomarin Pharmaceutical Inc (BMRN) Biomarin Pharmaceutical Inc (BMRN)